Blanket Purchase Agreement V797D30226-VA797P13A0008

This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Fera Pharmaceuticals, LLC, a woman-owned small business. The BPA, valued at up to $255,000, is for the procurement of Phospholine Iodide, a pharmaceutical drug. The BPA was awarded under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and allows the VA and other agencies to efficiently and compliantly acquire the needed pharmaceutical product from Fera...

This Blanket Purchase Agreement was awarded by the Department of the Army Medical Command to Nephron Sterile Compounding Center LLC on March 1, 2020, with a potential value of $2.5 million. The BPA is for specialized compounded intravenous solutions with no set-aside used. The period of performance extends through the last date to order of September 30, 2023. The BPA facilitates recurring orders for specific pharmaceutical products and supplies, including Phenylephrine HCI Injection,...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to PTC Therapeutics, Inc. as the prime contractor. The BPA, valued at a ceiling of $12,500.00, is for the procurement of EMFLAZA, a medication. The BPA was awarded on March 9, 2024, with a period of performance ending on March 14, 2026. The contract was a single award, with no set-aside used. As a BPA, this contract provides a streamlined mechanism for the agency to order and...

The government has awarded a Blanket Purchase Agreement (BPA) to Nephron Sterile Compounding Center LLC, a woman-owned limited liability company, to provide pharmaceutical products and supplies to the Defense Health Agency (DHA). The BPA has a ceiling value of $4,000,000 and a period of performance through March 31, 2025. Under this BPA, Nephron has received two specific task orders to date. The first is a $20,625 firm fixed price award for various injectable pharmaceutical products including...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to Mayne Pharma Commercial LLC, doing business as Metrics Inc. The BPA is for the procurement of halobetasol and tazaroten pharmaceuticals under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The single-award BPA has a ceiling value of $5,216,518.00 and a period of performance through May 28, 2025. As a foreign-owned, for-profit manufacturer of goods, Mayne...

This Federal Supply Schedule (FSS) contract, awarded by the National Acquisition Center, a civilian federal agency, to Mayne Pharma Commercial LLC, doing business as Mayne Pharma, provides for the procurement of halobetasol and tazaroten pharmaceuticals. The single-award Blanket Purchase Agreement (BPA) has a ceiling value of $5,216,518.00 and a period of performance through May 28, 2025. As a foreign-owned, for-profit manufacturer of goods, Mayne Pharma was the successful offeror under this...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to HRA Pharma America, Inc. as the prime contractor. The BPA has a period of performance from June 10, 2025 to June 9, 2026 and a ceiling value of $1,386,062.00. The BPA is for the procurement of the pharmaceutical products Lysodren and Metopirone. No set-asides were used for this single-award contract. The purpose of this BPA is to establish a contract vehicle through which the...

This Blanket Purchase Agreement (BPA) contract was awarded by the National Acquisition Center, a civilian federal agency, to Merz Pharmaceuticals, LLC, a for-profit foreign-owned organization. The BPA is established under the GSA Federal Supply Schedule 61-IB for Pharmaceuticals and Drugs, with a ceiling value of $12,057,300.00 and a period of performance running through March 12, 2026. The purpose of this BPA is to provide the agency with the pharmaceutical products Ampyra and Inbrijia. No...

This Blanket Purchase Agreement was awarded by the Department of the Army Medical Command to Pharmedium Services, LLC for specialized compounded intravenous solutions. The potential value of the BPA is $2.5 million. The period of performance is from October 1, 2018 through September 30, 2023. The BPA will facilitate orders for various pharmaceutical supplies to support pharmacy operations at Tripler Army Medical Center in Hawaii. Products included under the BPA are OR syringes, pre-mixed...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian agency, to Civica Inc., a non-profit organization and manufacturer of goods. The BPA has a ceiling value of $625,000.00 and a period of performance ending on April 3, 2026. The BPA is for the procurement of the pharmaceutical products daptomycin, lorazepam, phenylephrine, and anectine. As a BPA, this contract vehicle allows the agency to place individual task orders for these products as needed...